If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the 12th biotech listing so far in 2026.
Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Parabilis Medicines CEO Mathai Mammen speaks about the biotech's record $670M IPO, its desmoid tumor pipeline and plans beyond…
Parabilis Medicines, the decade-old and well-funded
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in…
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted…
Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 million…
